In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more.

• Intro :38
• Welcome to another episode of Eye Care insider :52
• About Allisa Song 1:01
• I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02
• What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06
• Can this go on every eyedrop bottle? 6:49
• Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51
• Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15
• How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36
• What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04
• Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23
• Congratulations again Allisa 19:03
• You’ll be graduating from medical school pretty soon? 19:15
• Any final words to our listeners? 19:50
• Outro 20:26

 

Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame. 

We’d love to hear from you! Send your comments/questions to Dr. Mali at [email protected]. Follow us on Twitter @Healio_OSN. Song can be reached at [email protected].  

Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions.